Pejanovic-Skobic Natasa, Galic Kristina, Kapcevic Ilijana, Grgic Svjetlana, Vasilj Marina, Lakicevic Sandra, Bender Marija, Zovko Tanja
Clinic of Neurology, University Clinical Hospital Mostar, Mostar, BIH.
Department of Pulmonary Diseases and Tuberculosis, University Clinical Hospital Mostar, Mostar, BIH.
Cureus. 2023 Sep 3;15(9):e44598. doi: 10.7759/cureus.44598. eCollection 2023 Sep.
The main objective of this research is to determine the prevalence and characteristics of neurological manifestations in hospitalized patients with SARS-CoV-2 infection.
A cross-sectional study was conducted. 572 hospitalized patients at the COVID Department of Pulmonology of the Mostar University Clinical Hospital in the six-month period from October 31, 2020, to April 30, 2021, were included. We analyzed the incidence of neurological manifestations and the influence of comorbidities and metabolic syndrome on stroke incidence in COVID-19 patients. We analyzed hospital length of stay and mortality in patients with and without neurological manifestations. The research was conducted with respect to all the determinants of the Helsinki Declaration.
572 patients, 351 men (61.4%), and 221 women (38.6%) were included. A fatal outcome was present in a quarter of patients (25.3%). Neurological manifestations were found in 163 patients (28.5%). Myalgia was the most common (16.1%). The following were reported: headache (9.6%), loss of taste (7.34%), loss of smell (6.8%), and vertigo (2.5%). There was a significant difference regarding loss of smell between males and females (p=0.04). The cerebrovascular incident was present in 2.97% of patients and was more frequent in the group of patients with metabolic syndrome. Patients with neurological manifestations had a longer hospital stay, but it was not statistically significant (p=0.9319). The presence of neurological manifestations in general did not influence the mortality rate.
Patients with SARS-CoV-2 infection can present with neurologic findings such as myalgia, headache, loss of smell or taste, vertigo, as well as cerebrovascular incidents. Patients with neurological manifestations had longer hospital stays, but the presence of neurological manifestations in general did not influence the mortality rate.
本研究的主要目的是确定感染新型冠状病毒2（SARS-CoV-2）的住院患者神经表现的患病率及特征。
开展了一项横断面研究。纳入了2020年10月31日至2021年4月30日这六个月期间在莫斯塔尔大学临床医院肺病科新冠病房住院的572例患者。我们分析了神经表现的发生率以及合并症和代谢综合征对新冠患者中风发生率的影响。我们分析了有和没有神经表现的患者的住院时间和死亡率。本研究是按照《赫尔辛基宣言》的所有决定因素进行的。
纳入572例患者，其中男性351例（61.4%），女性221例（38.6%）。四分之一的患者（25.3%）出现了致命结局。163例患者（28.5%）有神经表现。肌痛最为常见（16.1%）。报告的其他症状如下：头痛（9.6%）、味觉丧失（7.34%）、嗅觉丧失（6.8%）和眩晕（2.5%）。男性和女性在嗅觉丧失方面存在显著差异（p = 0.04）。2.97%的患者发生了脑血管事件，在代谢综合征患者组中更为常见。有神经表现的患者住院时间更长，但差异无统计学意义（p = 0.9319）。总体而言，神经表现的存在并不影响死亡率。
感染SARS-CoV-2的患者可能出现肌痛、头痛、嗅觉或味觉丧失、眩晕等神经学表现以及脑血管事件。有神经表现的患者住院时间更长，但总体而言，神经表现的存在并不影响死亡率。
